N'-[2-(乙胺基)乙基]乙烷-1,2-二胺 | 137554-10-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N'-[2-(乙胺基)乙基]乙烷-1,2-二胺
• 英文名称: N-ethyldiethylenetriamine
• 英文别名: N~1~-(2-Aminoethyl)-N~2~-ethylethane-1,2-diamine；N'-[2-(ethylamino)ethyl]ethane-1,2-diamine
• CAS: 137554-10-0
• 化学式: C₆H₁₇N₃
• mdl: MFCD19206995
• 分子量: 131.221
• InChiKey: NVSOSQNIJKZFBR-UHFFFAOYSA-N

物化性质

• 沸点：
  215.9±8.0 °C(Predicted)
• 密度：
  0.881±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  9
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  50.1
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N'-[2-(乙胺基)乙基]乙烷-1,2-二胺 在 potassium carbonate 作用下， 以 氯仿 、 乙腈 为溶剂， 反应 36.0h， 生成 di-tert-butyl 7-(2-ethoxy-2-oxoethyl)-1,4,7-triazonane-1,4-dicarboxylate
  参考文献：
  名称：

  HNODThia：一种有前途的螯合剂，用于开发 64Cu 放射性药物

  摘要：

  在此，我们介绍了两种新型杂环三氮杂环壬烷 (tacn) 基螯合剂（H NODThia和NODThia-AcNHEt ）的铜（II）和锌（II）配合物的合成和配位化学。螯合剂 H NODThia进一步衍生得到新型 PSMA 生物共轭物 ( NODThia-PSMA ) 和双功能光活化氮杂大环类似物NODThia-PEG 3 -ArN 3 ，用于开发铜 64 放射性药物。对不同的金属结合螯合物进行了64 Cu 放射性标记实验，在室温下不到 10 分钟即可获得定量放射化学转化率 (RCC)。通过配体挑战和铜交换实验评估了NODThia-PSMA在人血浆中的体外稳定性。接下来，我们研究了光活化类似物 ( NODThia-PEG 3 -ArN 3 ) 在光诱导放射性标记蛋白质光放射合成中的可行性。以人血清白蛋白 (HSA) 作为模型蛋白和临床相关单克隆抗体制剂 MetMAb 进行一锅光缀合反应。通过

  DOI：

  10.1021/acs.inorgchem.3c01616
• 作为产物：
  描述：

  N-boc-(乙基氨基)乙醛 、 N-叔丁氧羰基-1,2-乙二胺 在 三乙酰氧基硼氢化钠 、 三乙胺 、 盐酸 作用下， 以 水 为溶剂， 生成 N'-[2-(乙胺基)乙基]乙烷-1,2-二胺
  参考文献：
  名称：

  Rigorous control of vesicle-forming lipid pKa by fluorine-conjugated bioisosteres for gene-silencing with siRNA

  摘要：

  While the influence of pK(a) provided by amine-containing materials in siRNA delivery vectors for use in genesilencing has been widely studied, there are little reports in which amine pK(a) is controlled rigorously by using bioisosteres and its effect on gene-silencing. Here, we report that amine pK(a) could be rigorously controlled by replacement of hydrogen atom(s) with fluorine atom(s). A series of mono- and di-amine lipids with a different number of fluorine atoms were synthesized. The pK(a) of the polyamine lipids was shifted to a lower value with an increase in the number of fluorine atoms. The optimal pK(a) for high gene-silencing efficiency varied according to the number of amine residues in the polyamine lipid. Whereas the endosomal escape ability of mono-amine lipid-containing lipid vesicles (LVs) depended on the pK(a), that of all tested di-amine lipid-containing LVs showed equal membrane-destabilizing activity. LVs showing moderately weak interactions with siRNA facilitated cytoplasmic release of siRNA, resulting in strong gene-silencing. These findings indicate that appropriate amine pK(a) engineering depending on the number of amines is important for the induction of effective RNA interference.

  DOI：

  10.1016/j.jconrel.2018.12.044

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU CANCER À MÉDIATION PAR L'EZH2
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2018081530A1

  公开（公告）日：2018-05-03

  Methods for designing bivalent compounds which selectively degrade/disrupt EZH2 and compositions and methods of using such degraders/disruptors to treat EZH2-mediated cancer are provided.

  提供的设计二价化合物的方法，这些化合物可选择性地降解/破坏EZH2，以及使用这种降解剂/破坏剂治疗EZH2介导的癌症的组合物和方法。
• [EN] AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME<br/>[FR] RÉACTIFS DE TRANSFECTION AMINÉS ET PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS
  申请人：LIFE TECHNOLOGIES CORP

  公开号：WO2012068176A1

  公开（公告）日：2012-05-24

  There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.

  本文提供了一种新型含胺转染化合物及其制备和使用方法。这些化合物通常是通过将一级胺与不饱和化合物反应而获得的。本文还提供了使用含胺转染化合物与其他化合物结合以封装生物活性剂（如核酸）制备的转染复合物。还描述了使用转染复合物进行体内或体外传递生物活性剂的方法。本发明的转染复合物具有很高的效力，因此与已知的类似转染化合物相比，可以在相对较低的剂量下有效调节生物活性。
• Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same
  申请人：Artzyme Biotech Corporation

  公开号：US20020165365A1

  公开（公告）日：2002-11-07

  The present invention relates to a synthetic catalyst of the following formula (A) which can selectively recognize and cleave a specific protein among a protein mixture, and to a method for selective cleavage of a target protein using the same: (R)(Z) n (A) in which n denotes an integer of 1 or more, R represents a material capable of selectively recognizing and binding a target protein, and Z represents a metal ion-ligand complex.

  本发明涉及一种合成催化剂，其化学式为(A)，可以在蛋白质混合物中选择性地识别和切割特定蛋白质，并且涉及使用该催化剂进行目标蛋白质的选择性切割的方法：(R)(Z)n(A)，其中n表示大于或等于1的整数，R代表能够选择性识别和结合目标蛋白质的材料，Z代表金属离子-配体复合物。
• Monomer Compound, Process for Producing the Same, Polymer Thereof, and Water-Based Curable Composition
  申请人：Kobata Masami

  公开号：US20080053835A1

  公开（公告）日：2008-03-06

  The present invention provides an α-oxoamide group- and (meth)acryloyloxy group-containing monomer compound represented by Formula (I) wherein Y is a C 1-6 straight-chain alkylene group which may be substituted with a C 1-6 organic group, R 1 is a C 1-16 organic group, R 2 is a hydrogen atom or a C 1-8 organic group, and R 3 is a hydrogen atom or a methyl group; a production process therefor; a polymer thereof; and an aqueous curable composition containing the polymer.

  本发明提供了一种α-氧酰胺基和（甲基）丙烯酰氧基含有的单体化合物，其化学式为（I），其中Y为C1-6直链烷基，可以被C1-6有机基替代，R1为C1-16有机基，R2为氢原子或C1-8有机基，R3为氢原子或甲基；其制备方法；其聚合物；以及含有该聚合物的水性固化组合物。
• Chemokine Receptor Modulators
  申请人：Clark Michael P.

  公开号：US20100029634A1

  公开（公告）日：2010-02-04

  The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof. These compounds, and pharmaceutical composition comprising such compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers

  该发明提供了公式(I)化合物及其药学上可接受的盐、溶剂合物、互变异构体、立体异构体和/或酯。这些化合物和包含这些化合物的药物组合物对于治疗或预防HIV感染以及治疗增生性疾病，如抑制各种癌症的转移具有用处。